The DOI matches its Crossref record; 307 of the 314 references it cites were found in a registry or an index; 93 of the 282 sources its claims cite were checked for support.
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Open accessAbstract
BSG/UK-PBC treatment and management guidelines for PBC.
Overview
CoChat Summary
TL;DR
This BSG/UK-PBC guideline provides 40 recommendations for diagnosing and managing primary biliary cholangitis, centred on UDCA 13–15 mg/kg/day first-line, OCA for inadequate response or intolerance, and life-long risk-stratified follow-up. It also covers symptom control, complications of advanced liver disease, special populations, and audit standards.
Key findings
- UDCA is recommended for all patients with PBC at 13–15 mg/kg/day, usually life-long if tolerated; a combined analysis of three trials (548 patients) showed a one-third reduction in risk of death or transplant for moderate to severe PBC, with survival free of liver transplantation improved in medium- and high-risk bilirubin groups and histological stage IV.
- In patients with inadequate response to UDCA or UDCA intolerance, defined as ALP >1.67 × ULN and/or elevated bilirubin <2 × ULN, OCA addition is recommended for consideration; in the phase III trial, biochemical response was 10% with placebo vs 47% with 10 mg OCA and 46% with 5–10 mg titrated OCA, and mean ALP decrease was 39% and 33% vs 5%, respectively.
- Risk stratification after 1 year of UDCA should use biochemical response indices; high-risk patients are those with ALP >1.67 × ULN and/or elevated bilirubin <2 × ULN, while low-risk patients are those without cirrhosis with ALP <1.67 × ULN and normal bilirubin.
- Symptom burden is common and does not correlate with disease stage: pruritus affects approximately 80% of patients at some time, fatigue is reported by over 50% and severe in 20%, osteoporosis affects 20–44%, and approximately one-third of patients with advanced disease develop oesophageal varices over a median of 5.6 years.
Methods
- This is a clinical practice guideline developed as a consensus document by the British Society of Gastroenterology Liver Section and UK-PBC, with a broad Guidelines Development Group including gastroenterologists, hepatologists, transplant physicians, liver pathologists, and patient representatives.
- Development used a systematic review of publications identified via PubMed, Medline, and Cochrane database searches completed in June 2017, in line with the AGREE II instrument; recommendations use the GRADE system (Strong/Weak; quality High/Moderate/Low/Very low).
- The guideline provides 40 recommendations and service standards/audit recommendations, covering diagnosis, drug therapy, symptom management, advanced liver disease, transplantation, pregnancy, overlap syndromes, familial screening, and patient support.
Limitations
- The paper states that there is no consensus on the optimal non-invasive strategy to stage and monitor disease progression, and insufficient evidence to recommend one risk score over another on the basis of head-to-head data.
- The paper states that OCA survival benefit has not yet been demonstrated, longer-term efficacy and generalisability need confirmation, and more experience is needed in patients with advanced liver disease; the pivotal trial included patients with cirrhosis but no patients with decompensation.
- The paper states that evidence for UDCA in pregnancy is limited, off-label therapies such as budesonide and fibrates are not recommended pending phase III trials, and many recommendations are graded Weak or based on Low/Very low quality evidence.
- Evident from the text: several recommendations rely on expert opinion or limited case-series data, and patients with PBC were not well represented in some cited studies, such as the Baveno VI varices studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
58 Valid · 6 Not valid · 89 Not checked · 33 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Data from the UK-PBC patient cohort have shown that there is significant variation in management between centres and individual clinicians.12”
§ The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines > Recommendation 19 > Symptom management
What the sources say
- Disputedcites [12] sourceExperimental — accuracy not yet measured
The Results (page unavailable) report no significant difference in UDCA use between specialist and nonspecialist centres (81% versus 80%) and similar response rates. The Discussion likewise says patients in the two settings were equally likely to receive UDCA. The paper does not assess variation between individual clinicians. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The majority of these patients will be positive for the PBC-specific nuclear antibodies.265”
§ The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines > Recommendation 32 > Management of special populations
What the sources say
- Disputedcites [265] Bizzaro, 2012, Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature, Clin Rev Allergy Immunol sourceExperimental — accuracy not yet measured
The indexed study summary (no page supplied) reports that 43 of 100 AMA-negative PBC sera reacted to a screening test that included both nuclear and mitochondrial antigens. Its antigen-specific results show PBC-specific nuclear-antibody reactivity in 32 of 100 sera, not a majority. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“PBC is characterised serologically by autoantibodies specific for mitochondrial, nuclear and centromere antigens, some of which are unique to PBC.66–78”
§ The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines > How is PBC diagnosed? > Blood tests
What the sources say
- Not checked — no full text of the sourcecites [66] Marzorati, 2016, Making sense of autoantibodies in cholestatic liver diseases, Clin Liver Dis source
- Not checked — no full text of the sourcecites [67] Walker, 1965, Serological tests in diagnosis of primary biliary cirrhosis, Lancet source
- Not checked — no full text of the sourcecites [68] Doniach, 1966, Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications, Clin Exp Immunol
- Partly supportedcites [69] sourceExperimental — accuracy not yet measured
The introduction (p. 277) reports that PBC sera contain antibodies directed against mitochondrial membranes, supporting the mitochondrial part of the sentence. This paper does not establish antibodies to nuclear or centromere antigens or identify any antibodies as unique to PBC; its Methods (p. 277) say the studied sera were selected for absence of antinuclear reactions. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [70] Ruffatti, 1985, Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis, J Clin Immunol source
- Not checked — no full text of the sourcecites [71] source
- Supportedcites [72] Lassoued, 1990, Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis, Gastroenterology source
The Introduction/Abstract (p.1) states the serological background the claim summarises: antimitochondrial antibodies in 83%-99% of patients with the M2 type 'closely associated with PBC', ANA in 24%-31% (38%-58% on Hep2), with five recognised patterns including centromere; the Immunological Results section reports anticentromere antibodies in their series (Table 4, Discussion: 7%). The 'unique to PBC' part is supported by the Discussion, which says antibodies to the 200-kDa nuclear-envelope polypeptide 'could be considered specific for PBC' and concludes on 'this specific marker of PBC'. This is a broad background sentence carried by a citation range (66-78), and our copy treats the topic accordingly. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [73] Nickowitz, 1994, Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis, Gastroenterology source
- Not checked — no full text of the sourcecites [74] source
- Partly supportedcites [75] sourceExperimental — accuracy not yet measured
Our copy of Moteki et al. (1996) supports only the mitochondrial half of the sentence: the Abstract states that 'a characteristic serological feature observed in sera from patients with PBC is the presence of high titers of autoantibodies directed against mitochondrial antigens (AMAs),' targeting the E2 components of PDC, BCOADC and OGDC, and Table 1 plus the Results show this reactivity is specific to PBC (0/135 controls across PSC, CAH, SLE and healthy volunteers), which covers 'some of which are unique to PBC.' Nothing in our copy addresses nuclear or centromere autoantibodies — searches for 'centromere', 'antinuclear/nuclear autoantibodies', 'sp100/gp210' returned only mitochondrial antigen material, and the Introduction explicitly notes 'two other PBC autoantigens are not contained in the construct' (protein X, E1a), not nuclear targets. The nuclear and centromere components of the citing sentence therefore rest on the other references in the 66–78 range, not on this source. (LLM, conf=0.80)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with PBC typically have an increased incidence, in both themselves and their families, of other autoimmune diseases (over half of patients with PBC have another autoimmune condition), reflecting shared genetic predisposition (most notably but not exclusively celiac disease, scleroderma, thyroid disease and Sjögren’s).37–43”
§ The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines > Background > Epidemiology
What the sources say
- Not checked — no full text of the sourcecites [37] source
- Not checked — no full text of the sourcecites [38] source
- Not checked — no full text of the sourcecites [39] source
- Partly supportedcites [40] sourceExperimental — accuracy not yet measured
The Discussion reports more autoimmune comorbidity in patients with PBC than in controls, and the Family History section reports increased rates of several autoimmune diseases among relatives. But the Discussion gives the rate in patients as 32%, not over half. It treats genetic predisposition as a hypothesis and does not establish the sentence’s reference to celiac disease. (LLM, conf=0.91)
- Could not verifycites [41] sourceExperimental — accuracy not yet measured
The Abstract discusses genetic susceptibility to PBC and says about 50% of patients have no symptoms—not that they have another autoimmune condition. The Discussion and familial-history section address PBC risk and antimitochondrial antibodies in relatives, but do not establish increased rates of other autoimmune diseases in patients or their families. Searches for the named autoimmune diseases and the claimed proportion found no supporting passage. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [42] source
- Not checked — no full text of the sourcecites [43] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Both enhanced liver fibrosis (ELF)105 and transient elastography (TE)106 107 (eg, FibroScan) have, in cross-sectional studies, shown accuracy in determining disease stage as confirmed by biopsy.”
§ The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines > Recommendation 3 > Role of liver biopsy and other staging investigations
What the sources say
- Supportedcites [105] source
This source is cited for the ELF portion of the sentence; separate citations accompany transient elastography. In the Results (‘Correlation of ELF with histology’), ELF scores correlated with biopsy staging, and the authors report that ELF was an accurate non-invasive marker of histological fibrosis. They also note overlap in scores at intermediate stages. (LLM, conf=0.92)
- Supportedcites [106] source
The citation to this paper supports the transient elastography (TE) portion of the sentence; ELF has a separate citation. The Discussion reports accurate prediction of biopsy-assessed fibrosis stage in patients with PBC or PSC, and the Liver Histology section describes how biopsy stages were determined. Page numbers were not supplied in our copy. (LLM, conf=0.93)
- Supportedcites [107] source
The citation to this paper is attached to transient elastography (TE), not ELF. In Patient Populations and Liver Histological Assessment (page unavailable), the diagnostic cohort underwent both TE and liver biopsy; Diagnostic Performance reports that TE correctly classified 74% of patients by histological fibrosis stage, with strongest performance for severe fibrosis and cirrhosis. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
70 more claims · 19 with their cited sources checked
Create a free account to see all 186 claims and to verify the 31 references still open.
- It may state two separate claims as one. 80
- Probably not a substantial claim. 44
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gene variants in HLA or IL-12 signaling have been associated with PBC, and most patients display autoreactive antibodies against mitochondrial antigens and subsequent failure of biliary transporters, e.g., anion exchange protein 2 (AE2) [177–179].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“PBC is an autoimmune disease that primarily involves the targeting of intrahepatic BECs and results in chronic liver inflammation and fibrosis, in which hepatocyte injury is secondary and only manifests in later stages due to increased inflammation and cholestasis leading to oxidative stress [177].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [177]
In the citing paper
“Instead, ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is used as a first-line therapy for PBC to reduce bile acid toxicity and, thus, liver inflammation and hepatocyte injury [177].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [177]
In the citing paper
“The available treatments for PBC patients are limited to ursodeoxycholic acid (UDCA) and the recently licenced obeticholic acid (OCA) as a second-line approach17,18.”
From Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice (2019) · cites this paper as [17]
Citations
Cites
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
A Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Malinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893
Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Research works printed but not linked: 4
- Roeb, 2014, [Hepatocellular carcinoma - current aspects of screening, surveillance and therapeutic strategies (revised EASL-EORTC recommendations)], Zentralbl Chir, 139, 175
- 10.1016/j.jhep.2015.05.022 · DOI · Paper page
- 10.1016/S0140-6736(96)04410-8 · DOI · Paper page
- 10.1002/hep.1840150518 · DOI · Paper page
Cited by
FXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 184
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
Ferrín, G., Misas, M. G., Amado, V., Rodríguez‐Perálvarez, M., & de la Mata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041266 · Cited by 148
“UDCA therapy improves liver biochemistry parameters and delays the progression of the disease to liver cirrhosis [68].”
BackgroundThe Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review
Lleò, A., Leung, P. S. C., Hirschfield, G. M., & Gershwin, E. M. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1697617 · Cited by 161
Self-citationYou, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
“[4,6–8] Independent of disease stage, many people living with PBC experience significant impairment to quality of life, particularly from fatigue and pruritus.[2,3,7] Histologic damage characterized by a granulomatous lymphocytic cholangitis is associated with abnormal serum liver tests, including elevated serum alkal…”
BackgroundSelf-citation
Metadata
- Authors
- Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., Tiniakos, D., Walmsley, M., Webster, G., & Jones, D. E. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College Hospital (GB)
- University of Oxford (GB)
- University of Liverpool (GB)
- PBC Foundation (GB)
- Newcastle University (GB)
- PSC Support (GB)
- Corresponding author
- Hirschfield, Gideon M
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2018-03-28
- Volume
- 67
- Issue
- 9
- Pages
- 1568-1594
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC6109281
- OpenAlex
- W2794998501
- Cited by
- 362
- References
- 314
- Citations by year
- 2026: 44 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 46 · 2021: 49 · 2020: 35 · 2019: 36 · 2018: 4
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research (NF-SI-0513-10091)
- University of Birmingham
- Medical Research Council (MR/L001489/1)
- Birmingham Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, autoimmune liver disease, ursodeoxycholic acid, obeticholic acid, second-line therapy, risk stratification, treatment response, antimitochondrial antibodies, cholestasis, symptom burden, disease progression, patient follow-up
- MeSH terms
- Alanine Transaminase, Alkaline Phosphatase, Autoantibodies, Bilirubin, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Gastroenterology, United Kingdom, Humans, Liver Cirrhosis, Biliary, Mitochondria, Predictive Value of Tests, Risk Factors, Sensitivity and Specificity, Societies, Medical, Ursodeoxycholic Acid, Biomarkers, Treatment Outcome, Disease Progression, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. https://app.cochat.ai/papers/10.1136/gutjnl-2017-315259
- The paper
- Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., Tiniakos, D., Walmsley, M., Webster, G., & Jones, D. E. J. (2018). The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. https://doi.org/10.1136/gutjnl-2017-315259
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.